TMCI vs UFPT
TMCI: Treace is a focused orthopedic medical device company specializing in innovative 3D bunion correction and foot surgery systems for hospitals and surgical centers. UFPT: A specialized contract manufacturer producing custom single-use and single-patient medical devices for major OEMs across minimally invasive surgery, wound care, orthopedics, and biopharma applications.
Side-by-side fundamentals
| Metric | TMCI | UFPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.97 | $237.96 | |
| Market cap as of 2026-07-23 | $258M | $1.9B | |
| P/E as of 2026-07-23 | n/a | 27.03 | |
| PEG as of 2026-07-23 | -0.35 | 3.50 | TMCI lower |
| Net margin as of 2026-07-23 | -29.4% | +11.3% | UFPT higher |
| Gross margin as of 2026-07-23 | +79.7% | +28.4% | TMCI higher |
| Operating margin as of 2026-07-23 | -28.2% | +15.2% | UFPT higher |
| ROE as of 2026-07-23 | -69.5% | +16.6% | UFPT higher |
| ROA as of 2026-07-23 | -31.4% | +10.5% | UFPT higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.31 | UFPT lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.7% | +11.2% | UFPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.5% | +22.7% | UFPT higher |
| Beta as of 2026-07-23 | 1.40 | 1.07 | |
| 1-year return as of 2026-07-22 close | -26.0% | +3.0% | UFPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.